Nothing Special   »   [go: up one dir, main page]

CO5660262A2 - Composicion farmaceutica que contiene un inhibidor de histona deacetilasa - Google Patents

Composicion farmaceutica que contiene un inhibidor de histona deacetilasa

Info

Publication number
CO5660262A2
CO5660262A2 CO05129159A CO05129159A CO5660262A2 CO 5660262 A2 CO5660262 A2 CO 5660262A2 CO 05129159 A CO05129159 A CO 05129159A CO 05129159 A CO05129159 A CO 05129159A CO 5660262 A2 CO5660262 A2 CO 5660262A2
Authority
CO
Colombia
Prior art keywords
group
carbons
optionally substituted
pharmaceutical composition
formula
Prior art date
Application number
CO05129159A
Other languages
English (en)
Inventor
Osama Nakanishi
Tatsuo Sugawara
Hideyuki Migita
Yasuhiro Matsuba
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CO5660262A2 publication Critical patent/CO5660262A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.- Una composición o una combinación farmacéutica que comprende como ingredientes activos:a).- por lo menos uno de los derivados de benzamida que es una sustancia inhibidora de histona deacetilasa, o una sal farmacéuticamente aceptable de la misma, representado por la siguiente fórmula (I):en la cual A es un grupo fenilo opcionalmente sustituido o un grupo heterocíclico opcionalmente sustituido en el cual el/los sustituyente(s) para el grupo fenilo o para el grupo heterocíclico es(son): de 1 a 4 sustituyentes seleccionados entre el grupo consistente en un átomo de halógeno, un grupo hidroxilo, un grupo amino, un grupo nitro, un grupo ciano, un grupo alquilo que tiene 1 a 4 carbonos, un grupo alcoxi que tiene 1 a 4 carbonos, un grupo aminoalquilo que tiene 1 a 4 carbonos, un grupo alquilamino que tiene 1 a 4 carbonos, un grupo acilo que tiene 1 a 4 carbonos, un grupo acilamino que tiene 1 a 4 carbonos, un grupo alquiltío que tiene 1 a 4 carbonos, un grupo perfluoralquilo que tiene 1 a 4 carbonos, un grupo perfluoralquiloxi que tiene 1 a 4 carbonos, un grupo carboxilo, un grupo alcoxicarbonilo que tiene 1 a 4 carbonos, un grupo fenilo y un grupo heterociclico;X es un enlace o una parte que tiene una estructura seleccionada entre las ilustradas en la fórmula (2):en la cual e es un número entero de 1 a 4; g y m son independientemente un número entero de 0 a 4; R4 es un átomo de hidrógeno o un grupo alquilo opcionalmente sustituido que tiene 1 a 4 carbonos, o el grupo acilo representado por la fórmula (3): en la cual R6 es un grupo alquilo opcionalmente sustituido que tiene 1 a 4 carbonos, ...
CO05129159A 2003-05-26 2005-12-22 Composicion farmaceutica que contiene un inhibidor de histona deacetilasa CO5660262A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003148073 2003-05-26

Publications (1)

Publication Number Publication Date
CO5660262A2 true CO5660262A2 (es) 2006-07-31

Family

ID=33475383

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05129159A CO5660262A2 (es) 2003-05-26 2005-12-22 Composicion farmaceutica que contiene un inhibidor de histona deacetilasa

Country Status (27)

Country Link
US (1) US20070098816A1 (es)
EP (1) EP1626719A1 (es)
JP (1) JP2006526031A (es)
KR (1) KR100938712B1 (es)
CN (2) CN101322707A (es)
AR (1) AR045318A1 (es)
AU (1) AU2004241873C1 (es)
BR (1) BRPI0410959A (es)
CA (4) CA2527191A1 (es)
CL (1) CL2004001278A1 (es)
CO (1) CO5660262A2 (es)
CR (1) CR8163A (es)
CU (1) CU23490B7 (es)
EC (1) ECSP056253A (es)
IL (1) IL171941A0 (es)
ME (1) MEP32308A (es)
MX (1) MXPA05012345A (es)
NO (1) NO20055417L (es)
NZ (1) NZ543591A (es)
PE (1) PE20050206A1 (es)
RS (1) RS20050884A (es)
RU (1) RU2322971C2 (es)
TW (1) TW200505424A (es)
UA (1) UA81499C2 (es)
UY (1) UY28330A1 (es)
WO (1) WO2004103369A1 (es)
ZA (1) ZA200509515B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
PL2263694T3 (pl) 2003-09-25 2013-11-29 Astellas Pharma Inc Środek przeciwnowotworowy zawierający FK228 jako inhibitor deacetylazy histonowej i doksorubicynę jako inhibitor topoizomerazy II
US7446126B2 (en) * 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
EP1712552A1 (en) * 2005-04-11 2006-10-18 INDENA S.p.A. Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
MX2007011148A (es) * 2005-03-11 2008-02-22 Univ Colorado Inhibidores de histona desacetilasa que sensibilizan celulas cancerosas respecto a los inhibidores de factor de crecimiento.
JP5744376B2 (ja) 2005-03-22 2015-07-08 プレジデント アンド フェローズ オブ ハーバード カレッジ タンパク質分解障害の治療
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
DK2010168T3 (da) * 2006-02-14 2014-07-21 Harvard College Histondeacetylase-inhibitore
AU2007345292B2 (en) 2006-02-14 2013-10-31 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
CA2654540C (en) 2006-05-03 2017-01-17 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
WO2008082856A1 (en) 2006-12-26 2008-07-10 Pharmacyclics, Inc. Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
CA2709383A1 (en) * 2007-12-14 2009-06-25 Milton L. Brown Histone deacetylase inhibitors
CA2731730C (en) 2008-07-23 2017-06-13 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
PE20141062A1 (es) * 2008-08-29 2014-09-19 Bayer Ip Gmbh Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
AU2009327357C1 (en) 2008-12-19 2017-02-02 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of ATR kinase
US20120034302A1 (en) * 2009-02-11 2012-02-09 Liangping Yu Particulate composition and the method of making the same
CN102573826A (zh) * 2009-05-01 2012-07-11 奥克兹美制药公司 用于治疗癌症的喷他脒组合
US8258316B2 (en) * 2009-06-08 2012-09-04 Gilead Sciences, Inc. Alkanoylamino benzamide aniline HDAC inhibitor compounds
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
UA110196C2 (uk) * 2009-08-25 2015-12-10 Абраксіс Байосайєнс, Елелсі Комбінована терапія композиціями наночастинок таксану і інгібіторами хеджхог
EP2569313A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
KR101892788B1 (ko) 2011-09-13 2018-08-28 파마싸이클릭스 엘엘씨 벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도
KR102056586B1 (ko) 2011-09-30 2019-12-18 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 억제제를 이용한 췌장암 및 비소세포 폐암의 치료
EP2751097A2 (en) 2011-09-30 2014-07-09 Vertex Pharmaceuticals Incorporated Processes for making compounds useful as inhibitors of atr kinase
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
NZ726671A (en) 2012-04-05 2018-04-27 Vertex Pharma Compounds useful as inhibitors of atr kinase and combination therapies thereof
EP2904406B1 (en) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
EP2968282B1 (en) 2013-03-12 2018-05-09 Celgene Quanticel Research, Inc. Histone dementhylase inhibitors
US9963452B2 (en) * 2013-03-14 2018-05-08 Augusta Pharmaceuticals Inc. Methods, compounds, and compositions for inhibition of ROS
WO2015127227A1 (en) * 2014-02-21 2015-08-27 Cleveland Biolabs, Inc. Uses of flagellin for improved chemotherapy
EP3194387B1 (en) 2014-09-17 2019-07-31 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
HUP0103640A3 (en) * 1998-09-25 2003-01-28 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
ATE506967T1 (de) * 1999-04-27 2011-05-15 Mitsubishi Tanabe Pharma Corp Arzneimittel zur präventiven oder therapeutische behandlung von lebererkrankungen
KR20020060226A (ko) * 1999-11-10 2002-07-16 로즈 암스트롱, 크리스틴 에이. 트러트웨인 배합 화학요법
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体

Also Published As

Publication number Publication date
ECSP056253A (es) 2006-10-25
RS20050884A (en) 2008-04-04
MEP32308A (en) 2010-10-10
NO20055417L (no) 2005-12-19
KR20060009371A (ko) 2006-01-31
PE20050206A1 (es) 2005-03-26
BRPI0410959A (pt) 2006-07-04
AU2004241873A1 (en) 2004-12-02
TW200505424A (en) 2005-02-16
CR8163A (es) 2006-07-14
CA2634766A1 (en) 2004-12-02
AU2004241873B8 (en) 2008-05-29
NO20055417D0 (no) 2005-11-16
RU2005140570A (ru) 2006-06-10
MXPA05012345A (es) 2006-02-08
NZ543591A (en) 2009-09-25
ZA200509515B (en) 2006-07-26
JP2006526031A (ja) 2006-11-16
CA2634765A1 (en) 2004-12-02
CA2527191A1 (en) 2004-12-02
KR100938712B1 (ko) 2010-01-25
AR045318A1 (es) 2005-10-26
CA2634709A1 (en) 2004-12-02
EP1626719A1 (en) 2006-02-22
CN101322707A (zh) 2008-12-17
RU2322971C2 (ru) 2008-04-27
IL171941A0 (en) 2006-04-10
UA81499C2 (en) 2008-01-10
US20070098816A1 (en) 2007-05-03
CL2004001278A1 (es) 2005-05-06
AU2004241873C1 (en) 2009-01-22
CU23490B7 (es) 2010-02-23
UY28330A1 (es) 2004-12-31
WO2004103369A1 (en) 2004-12-02
CN1794991A (zh) 2006-06-28
AU2004241873B2 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
CO5660262A2 (es) Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
AR036597A1 (es) Derivados de 1h-imidazol que tienen actividad agonista de cb1, agonista parcial de cb1 o antagonista de cb1
BRPI0515594B8 (pt) compostos inibidores da interação entre mdm2 e p53,composição farmacêutica, processo para a preparação desta composição farmacêutica, usos dos compostos, suas combinações e processo para a preparação destes compostos
ECSP088457A (es) Compuestos de benzamida útiles como inhibidores de la histona deacetilasa
PE20070078A1 (es) Compuestos heterociclicos macrociclicos como inhibidores de aspartil proteasa
EA200001122A1 (ru) Ингибиторы синтазы оксида азота
ATE389635T1 (de) Pharmazeutisch wirksame piperidinderivate
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
FR2838439B1 (fr) Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
DE60305724D1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
HUP0402679A2 (hu) Pirrolidin- és piperidin-származékok mint NK1 antagonisták és a vegyületeket tartalmazó gyógyszerkészítmények
NO20024614L (no) N-heterosykliske derivater som NOS-hemmere
EA200500312A1 (ru) Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз
WO2005030766A8 (en) Phenyl - carboxamide compounds useful for treating pain
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
MXPA05011176A (es) Derivados de carboxamida como agentes antidiabeticos.
DE60014404D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
ES2632798T3 (es) Uso de derivados de cumarina para la preparación de fármacos de tratamiento de enfermedades de la piel
AR063576A1 (es) Arilsulfonil- pirrolidinas como inhibidores 5-ht6
DE60014394D1 (de) Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha
EA200501513A1 (ru) Замещённые 1, 4 - диазепины и их применения
AR062941A1 (es) Compuestos para el tratamiento de desordenes metabolicos
WO2004067703A3 (en) 5ht7 antagonists and inverse agonists
AR045816A1 (es) Derivados de carboxamida